Control of type II transforming growth factor-β receptor expression by integrin ligation

被引:45
|
作者
Wang, DH
Sun, LZ
Zborowska, E
Willson, JKV
Gong, JG
Verraraghavan, J
Brattain, MG
机构
[1] Univ Texas, Hlth Sci Ctr, Dept Surg, San Antonio, TX 78284 USA
[2] Univ Texas, Hlth Sci Ctr, Dept Biochem, San Antonio, TX 78284 USA
[3] Univ Kentucky, Dept Pharmacol, Lexington, KY 40536 USA
[4] Case Western Reserve Univ, Ireland Canc Ctr, Dept Med, Cleveland, OH 44106 USA
[5] Sch Med, Cleveland, OH 44106 USA
[6] Med Coll Ohio, Dept Biochem, Toledo, OH 43699 USA
关键词
D O I
10.1074/jbc.274.18.12840
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Ectopic expression of the alpha(5) integrin subunit in cancer cells with little or no endogenous expression of this integrin often results in reduced proliferation as well as reduced malignancy, We now show that inhibition resulting from ectopic expression of alpha(5) integrin is due to induction of autocrine negative transforming growth factor-beta (TGF-beta) activity. MCF-7 breast cancer cells do not express either alpha(5) integrin or type II TGF-beta receptor and hence are unable to generate TGF-beta signal transduction. Ectopic expression of cy,integrin expression enhanced cell adhesion to fibronectin, reduced proliferation, and increased the expression of type II TGF-beta receptor mRNA and cell surface protein. Receptor expression was increased to a higher level in alpha(5) transfectants by growth on fibronectin-coated plates. Induction of type II TGF-beta receptor expression also resulted in the generation of autocrine negative TGF-beta activity because colony formation was increased after TGF-beta neutralizing antibody treatment. Transient transfection with a TGF-beta promoter response element in tandem with a luciferase cDNA into cells stably transfected with cu, integrin resulted in basal promoter activities 5-10-fold higher than those of control cells. Moreover, when alpha(5) transfectants were treated with a neutralizing antibody to either TGF-beta or integrin alpha(5), this increased basal promoter activity was blocked, Autocrine TGF-beta activity also induced 3-fold higher endogenous fibronectin expression in alpha(5) transfectants relative to that of control cells, Re-expression of type II receptor by alpha(5) transfection also restored the ability of the cells to respond to exogenous TGF-beta and led to reduced tumor growth in athymic nude mice. Taken together, these results show for the first time that TGF-beta type II receptor expression can be controlled by alpha(5)beta(1) ligation and integrin signal transduction, Moreover, TGF-beta and integrin signal transduction appear to cooperate in their tumor-suppressive functions.
引用
收藏
页码:12840 / 12847
页数:8
相关论文
共 50 条
  • [21] Expression of epidermal growth factor, transforming growth factor-α and their receptor in the human oesophagus
    Calabrò, A
    Orsini, B
    Renzi, D
    Papi, L
    Surrenti, E
    Amorosi, A
    Herbst, H
    Milani, S
    Surrenti, C
    HISTOCHEMICAL JOURNAL, 1997, 29 (10): : 745 - 758
  • [22] Hepatic fibrosis and hepatocarcinogenesis;: Studies of transforming growth factor-β receptor II expression.
    Ueno, A
    Hashimoto, O
    Kimura, R
    Nakamura, T
    Sakata, R
    Torimura, T
    Kawaguchi, T
    Koga, H
    Yutani, S
    Sakisaka, S
    Tanikawa, K
    Sata, M
    HEPATOLOGY, 1999, 30 (04) : 258A - 258A
  • [23] Upregulated expression of transforming growth factor-β receptor I/II in an endemic Osteoarthropathy in China
    Zhang, Ying
    Mu, Yudong
    He, Ying
    Li, Zhengzheng
    Mi, Ge
    Liu, Yinan
    Zhang, Meng
    Wang, Hui
    Feng, Yiping
    Fang, Qian
    Ma, Tianyou
    Deng, Xianghua
    Chen, Jinghong
    BMC MUSCULOSKELETAL DISORDERS, 2021, 22 (01)
  • [24] Upregulated expression of transforming growth factor-β receptor I/II in an endemic Osteoarthropathy in China
    Ying Zhang
    Yudong Mu
    Ying He
    Zhengzheng Li
    Ge Mi
    Yinan Liu
    Meng Zhang
    Hui Wang
    Yiping Feng
    Qian Fang
    Tianyou Ma
    Xianghua Deng
    Jinghong Chen
    BMC Musculoskeletal Disorders, 22
  • [25] Microsatellite mutation of type II transforming growth factor-β receptor is rare in atherosclerotic plaques
    Clark, KJ
    Cary, NR
    Grace, AA
    Metcalfe, JC
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2001, 21 (04) : 555 - 559
  • [26] Relation of type II transforming growth factor-β receptor to hepatic fibrosis and hepatocellular carcinoma
    Ueno, T
    Hashimoto, O
    Kimura, R
    Torimura, T
    Kawaguchi, T
    Nakamura, T
    Sakata, R
    Koga, H
    Sata, M
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2001, 18 (01) : 49 - 55
  • [27] Methylation silencing of transforming growth factor-β receptor type II in rat prostate cancers
    Yamashita, Satoshi
    Takahashi, Satoru
    McDonell, Nathalie
    Watanabe, Naoko
    Niwa, Tohru
    Hosoya, Kosuke
    Tsujino, Yoshimi
    Shirai, Tomoyuki
    Ushijima, Toshikazu
    CANCER RESEARCH, 2008, 68 (07) : 2112 - 2121
  • [28] Expression of recombinant human soluble type II transforming growth factor-β receptor in Pichia pastoris and Escherichia coli:: Two powerful systems to express a potent inhibitor of transforming growth factor-β
    Glansbeek, HL
    van Beuningen, HM
    Vitters, EL
    van der Kraan, PM
    van den Berg, WB
    PROTEIN EXPRESSION AND PURIFICATION, 1998, 12 (02) : 201 - 207
  • [29] Abnormalities in expression of genes, mRNA, and proteins of transforming growth factor-β receptor type I and type II in human pituitary adenomas
    Fujiwara, K
    Ikeda, H
    Yoshimoto, T
    CLINICAL NEUROPATHOLOGY, 1998, 17 (01) : 19 - 26
  • [30] Transforming growth factor-β isoform and receptor expression in chondrosarcoma of bone
    Laura Masi
    Cecilia Malentacchi
    Domenico Campanacci
    Alessandro Franchi
    Virchows Archiv, 2002, 440 : 491 - 497